Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a pioneering biopharmaceutical company devoted to advancing the development of tecarfarin, an innovative anticoagulant (blood thinner). Tecarfarin is designed to reduce the risk of heart attacks, strokes, and fatalities caused by blood clots in patients with specific, rare cardiovascular conditions.
This novel therapy, currently in its late-stage of development, shows promise for patients suffering from conditions where traditional anticoagulants, such as warfarin and direct oral anticoagulants (DOACs) like Eliquis, fall short. Tecarfarin targets different metabolic pathways, which could provide more stable anticoagulation compared to warfarin, and is particularly significant for patients with end-stage kidney disease (ESKD) and atrial fibrillation (AFib).
Recent developments have highlighted tecarfarin's potential benefits:
- Cadrenal has secured orphan drug designation (ODD) from the FDA for tecarfarin's use in preventing thromboembolism and thrombosis in patients with mechanical circulatory support devices, such as left ventricular assist devices (LVADs). This designation offers incentives such as clinical research tax credits and seven years of market exclusivity post-approval.
- The company is exploring strategic partnerships and licensing agreements with The Sage Group, aiming to enhance clinical development and regulatory strategies globally.
- Tecarfarin has demonstrated efficacy in eleven human clinical trials involving over 1,000 individuals, showing generally good tolerance in both healthy subjects and those with chronic kidney disease.
- Cadrenal has also managed cash resources effectively, maintaining substantial financial flexibility, with significant cash reserves to continue advancing towards pivotal trials expected to commence in 2024.
As Cadrenal moves forward, its efforts are bolstered by the growing body of evidence supporting the need for a reliable Vitamin K antagonist (VKA) like tecarfarin. This is especially crucial for patients with LVADs and other conditions where DOACs are contraindicated or ineffective. For more information, please visit: www.cadrenal.com.
Cadrenal Therapeutics (CVKD) has appointed James J. Ferguson, MD, FACC, FAHA as its new Chief Medical Officer, replacing Douglas W. Losordo, MD. Dr. Ferguson, with over 25 years of cardiovascular leadership experience, will lead the late-stage clinical development of tecarfarin, a new Vitamin K antagonist, focusing on pivotal trials in LVAD patients and other rare cardiovascular conditions requiring life-long anticoagulation therapy.
Dr. Ferguson joins from Matinas BioPharma, where he served as Chief Medical Officer. His previous roles include Head of U.S. Cardiovascular Medical Affairs at Amgen and various senior positions at AstraZeneca. The appointment aims to advance tecarfarin's development as the first innovation in vitamin K-targeted anticoagulation in 70 years.
Cadrenal Therapeutics (Nasdaq: CVKD), a late-stage biopharmaceutical company, will deliver a presentation at the 2025 BIO CEO & Investor Conference at The New York Marriott Marquis on February 10-11, 2025. CEO Quang X. Pham will present on February 10 at 4:30 pm EST in the Royale Room, providing company updates and details about their lead product tecarfarin.
The presentation will focus on tecarfarin, a novel Vitamin K antagonist (VKA) being developed as a safer anticoagulant alternative to warfarin for patients with implanted cardiac devices. Mr. Pham will be available for one-on-one meetings through the BIO partnering portal during the conference.
Cadrenal Therapeutics (Nasdaq: CVKD) has announced its participation in the upcoming Lytham Partners 2025 Investor Healthcare Summit, scheduled for January 13, 2025. The company's Chairman and CEO, Quang X. Pham, will engage in a virtual fireside chat at 10:30 a.m. Eastern time.
Cadrenal Therapeutics specializes in developing tecarfarin, a novel oral vitamin K antagonist (VKA) currently in advanced clinical development. This therapeutic is designed to provide a superior and safer anticoagulation alternative for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
The virtual event will be accessible through the conference website, with replay options available. Interested investors can request one-on-one meetings through Lytham Partners representatives.
Cadrenal Therapeutics (CVKD) provided its 2024 year-end update, highlighting progress in developing tecarfarin for left ventricular assist device (LVAD) patients and rare cardiovascular conditions. Key achievements include: FDA Orphan Drug Designation for tecarfarin in LVAD patients, successful fundraising of $9.8 million bringing cash balance to $11.3 million, and completion of manufacturing readiness for the upcoming Phase 3 trial.
The company held a Type B meeting with the FDA regarding the pivotal Phase 3 trial protocol, with updates expected in Q1 2025. Tecarfarin aims to provide a superior alternative to warfarin for chronic anticoagulation in LVAD patients. The company also joined the Anticoagulation Forum and was named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook.
Cadrenal Therapeutics (CVKD) announces its participation in three key events during the 43rd Annual J.P. Morgan Healthcare Conference Week in January 2025. The company will present updates on tecarfarin, their novel oral vitamin K antagonist designed for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions.
CEO Quang X. Pham will participate in the Longwood Healthcare Leaders discussions on January 11-12, attend the Nasdaq Opening Bell Ceremony on January 13, and along with COO Jeff Cole, will conduct one-on-one investor meetings during the conference. The company plans to outline its Phase 3 clinical development plan, regulatory approval strategy, and three-year vision.
Cadrenal Therapeutics (Nasdaq: CVKD) has been named '2024 Anticoagulation Therapy Company of the Year' by Pharma Tech Outlook for its development of tecarfarin, a new vitamin K antagonist anticoagulant. The company is developing tecarfarin as a potentially safer alternative to warfarin for patients with implanted left ventricular assist devices (LVADs) and rare cardiovascular conditions. Unlike warfarin, tecarfarin uses a unique metabolic pathway less affected by drug-drug interactions and kidney impairment. The drug has received orphan drug and fast-track designations, positioning it to address unmet needs in chronic anticoagulation treatment.
Cadrenal Therapeutics (CVKD) highlighted a presentation at the EACTS Medical Congress featuring tecarfarin data and their proposed clinical trial protocol. The presentation, titled Tecarfarin and Hemocompatibility with LVAD Therapy (TECH-LVAD), focused on evaluating tecarfarin versus warfarin in patients with Abbott HeartMate3 left ventricular assist device. Dr. Mandeep R. Mehra presented data showing the relationship between bleeding rates and time in therapeutic range for HM3 patients, and evidence of tecarfarin's potential to improve TTR. The presentation also highlighted that end-stage kidney disease doesn't alter tecarfarin exposure, unlike warfarin, which is significant as many LVAD patients have kidney impairment.
Cadrenal Therapeutics (NASDAQ: CVKD) provided a Q3 2024 corporate update highlighting progress in developing tecarfarin, a new vitamin K antagonist for anticoagulation. Key developments include FDA discussions regarding Phase 3 trial protocol for LVAD patients, advancement of Abbott collaboration talks, and joining the Anticoagulation Forum's Corporate Council. The company successfully raised $9.8 million through ATM and warrant exercises, increasing cash balance to $11.3 million. Q3 operating expenses were $2.5 million, with $2.2 million used in operating activities. Tecarfarin is positioned as the only anticoagulant in development for patients with implanted cardiac devices and rare cardiovascular conditions.
Cadrenal Therapeutics (CVKD) announced the exercise of warrants to purchase 285,715 shares of common stock at a reduced price of $16.50 per share, down from the original $26.25. The company will issue new unregistered Series A-1 and A-2 warrants, each for 285,715 shares at $16.50 per share. The gross proceeds are expected to be $4.7 million, which will be used for pivotal Phase 3 trial and partnering activities. The new warrants will have terms of five years and eighteen months respectively, and the company will file a registration statement for the resale of shares.
Cadrenal Therapeutics (NASDAQ: CVKD) has successfully raised $5.1 million through an at-the-market (ATM) facility by selling 391,243 shares of common stock at an average price of $13.15 per share. Following this transaction, the company now has 1,496,771 shares outstanding and a cash balance of approximately $7.4 million. The funds will support the development of tecarfarin, a new vitamin K antagonist for patients with implanted cardiac devices or rare cardiovascular conditions, including preparation for a pivotal Phase 3 trial and ongoing partnering activities.
FAQ
What is the current stock price of Cadrenal Therape (CVKD)?
What is the market cap of Cadrenal Therape (CVKD)?
What is Cadrenal Therapeutics' primary focus?
What is tecarfarin?
What recent achievements has Cadrenal Therapeutics made?
How has tecarfarin performed in clinical trials?
What financial condition is Cadrenal Therapeutics in?
Why is tecarfarin significant for patients with LVADs?
What regulatory benefits does tecarfarin have?
What partnerships has Cadrenal Therapeutics formed?
What market need does tecarfarin address?
Where can I find more information about Cadrenal Therapeutics?
